 
Antibodies such as 225-28S are directed to a high molecular weight melanoma-associated antigen (HMW-MAA),3 which is expressed in about 90% of the cutaneous melanomas. 14 15 Expression of the HMW-MAA in uveal melanoma was found to occur in 40 to 50% of cases.'2 16 The Itechnetium-labelled antibody 225 28S has been used for immunoscintigraphy in uveal melanoma patients and yielded detection percentages from 37% to 64%.'7-'9 The use of sophisticated equipment like single photon emission computerised tomography (SPECT) or a 'double pinhole' collimator enhanced the detection percentages to 73% to 92%. '7-'9 In view of the results of the relatively low in-situ expression of the HMW-MAA in uveal melanoma in previous studies'2 16 Scintigraphy results of another study showed a higher detection rate with MoAb 225 28S. An explanation for this difference may be the performance of three scans after injection of the antibody24 as compared with one scan in our study.'9 Performance of several scans at standard consecutive time intervals may provide information on the distribution of activity in the course of time. A specific activity in the vessels is high directly after injection of the antibody and then decreases, while a specific binding of antibody to the antigen needs some time to become established, and specific tracer uptake will increase on the consecutive images.
An important limiting factor is the high nonspecific background activity in the nasopharyngeal region, but the use of single photon emission computerised tomography enables the physician adequately to differentiate the tumour from the nasopharyngeal activity. 
